Hepatology Unit, Department of Internal Medicine, Tor Vergata University, Via Montpellier 1-00133 Rome, Italy.
Dig Liver Dis. 2010 Aug;42(8):578-84. doi: 10.1016/j.dld.2009.12.003. Epub 2010 Jan 22.
Life-long prophylaxis against HBV recurrence is recommended in patients transplanted for HBV-related disease. The risk of HBV reactivation is due to persistence of covalently closed circular (ccc) DNA in hepatocytes. Whether cccDNA persists in livers of long-term transplant survivors who received conventional prophylaxis is unknown.
To investigate the presence of intrahepatic total and cccDNA in transplanted patients with no evidence of biochemical markers of HBV recurrence.
Intrahepatic total and cccDNA were assessed using sensitive nested and real-time PCR from 44 HBsAg-positive patients (75% male; mean age 55.2+/-8.9 years) who had undetectable serum HBV-DNA at transplant. The mean follow-up after transplant was 88.3 months (range, 18-159).
One patient underwent HBV recurrence after transplant and was the only who tested positive for both intrahepatic total HBV-DNA and cccDNA. Of the 43 patients negative for all serological markers of HBV infection, only 2 tested positive for intrahepatic total HBV-DNA, but none for cccDNA.
Most patients with undetectable HBV-DNA at transplant, who received conventional HBV prophylaxis, have no evidence of intrahepatic total HBV-DNA and cccDNA. cccDNA should be considered a new additional diagnostic tool, also to identify patients at low risk of HBV recurrence after liver transplantation.
对于因乙型肝炎病毒(HBV)相关疾病而接受移植的患者,建议终身预防 HBV 复发。HBV 再激活的风险源于肝细胞内共价闭合环状(ccc)DNA 的持续存在。接受常规预防治疗的长期移植存活者肝脏中是否存在 cccDNA 尚不清楚。
研究在无 HBV 复发生化标志物证据的移植患者中肝内总 DNA 和 cccDNA 的存在情况。
采用敏感的巢式和实时 PCR 法检测 44 例 HBsAg 阳性患者(75%为男性;平均年龄 55.2±8.9 岁)肝内总 DNA 和 cccDNA,这些患者在移植时血清 HBV-DNA 不可检测。移植后平均随访 88.3 个月(范围 18-159 个月)。
1 例患者在移植后发生 HBV 复发,且是唯一 1 例同时检测到肝内总 HBV-DNA 和 cccDNA 阳性的患者。在 43 例所有乙型肝炎病毒感染血清学标志物均为阴性的患者中,仅 2 例检测到肝内总 HBV-DNA 阳性,但均未检测到 cccDNA。
大多数在移植时 HBV-DNA 不可检测且接受常规 HBV 预防治疗的患者,肝内无总 HBV-DNA 和 cccDNA 证据。cccDNA 可作为新的辅助诊断工具,也可用于识别肝移植后 HBV 复发风险低的患者。